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Distribution of RET Mutations in Multiple Endocrine
Neoplasia 2 in Denmark 1994–2014:
A Nationwide Study
Jes Sloth Mathiesen,1,2 Jens Peter Kroustrup,3 Peter Vestergaard,3 Kirstine Stochholm,4
Per Løgstrup Poulsen,4 Åse Krogh Rasmussen,5 Ulla Feldt-Rasmussen,5 Mette Gaustadnes,6
Torben Falck Ørntoft,6 Thomas van Overeem Hansen,7 Finn Cilius Nielsen,7
Kim Brixen,8 Christian Godballe,1 and Anja Lisbeth Frederiksen9
Background: Germline mutations of the REarranged during Transfection (RET) proto-oncogene cause multiple
endocrine neoplasia 2 (MEN2). It is unclear whether the distribution of RET mutations varies among popu-
lations. The first nationwide study of the distribution of RET mutations was conducted, and the results were
compared to those of other populations.
Methods: This retrospective cohort study included 1583 patients who underwent RET gene testing in one of
three centers covering all of Denmark between September 1994 and December 2014. Primary testing method
was Sanger sequencing, which included exons 8–11 and 13–16. Mutations were defined according to the ARUP
database July 1, 2016.
Results: RET mutations were identified in 163 patients from 36 apparently unrelated families. Among the 36
families 13 (36.1%) carried mutations in codon 611, four (11.1%) in codon 618, three (8.3%) in codon 620, one
(2.8%) in codon 631, six (16.7%) in codon 634, one (2.8%) in codon 790, one (2.8%) in codon 804, one (2.8%)
in codon 852, one (2.8%) in codon 883, and five (13.9%) in codon 918. Among the 13 families with codon 611
mutations, 12 had the p.C611Y mutation.
Conclusions: The distribution of RET mutations in Denmark appears to differ from that of other populations.
Mutations in codon 611 were the most prevalent, followed by more frequently reported mutations. This might
be due to a possible founder effect for the p.C611Y mutation. However, further studies are needed to find
possible explanations for the skewed mutational spectrum in Denmark.
Keywords: epidemiology, genetics, molecular biology, medullary thyroid carcinoma, medullary thyroid
carcinoma—genetics
Introduction
Multiple endocrine neoplasia 2 (MEN2) is an au-tosomal dominant inherited cancer syndrome sub-
divided into MEN2A and MEN2B. MEN2A associates
medullary thyroid carcinoma (MTC), pheochromocytoma
(PHEO), hyperparathyroidism (HPTH), cutaneous lichen
amyloidosis (CLA), and Hirschsprung’s disease (HD).
MEN2B associates MTC, PHEO, ganglioneuromatosis of
the aerodigestive tract, and facial, ophthalmologic, and
skeletal abnormalities (1).
MEN2A and 2B are caused by activating missense germ-
line mutations of the REarranged during Transfection (RET)
proto-oncogene. These pivotal discoveries were made in
1993 and 1994 (2–5), and since then, >100 mutations have
been identified (1).
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Codon 634 mutations are reported as the most prevalent in
both European (6–16) and non-European families (17–25).
However, a recent Greek study of 58 RET positive families
found mutations of codon 533 to be predominant (26). Smaller
studies from Portugal (27), Cyprus (28), and Sardinia (29) re-
vealed mutations prevailing in codons 611, 618, and 804, re-
spectively. Also, a large multicenter study of 250 families from
Italy showed an unusually high prevalence of codon 804 and
891 mutations (7). A high prevalence of codon 790 mutations
has been noted in Germany (6). Consequently, it is unclear
whether the distribution of RET mutations is comparable
among populations or whether geographical differences exist.
The first nationwide study of the distribution of RET mu-
tations was conducted, and the results were compared to
those of other populations.
Patients and Methods
Patients
This retrospective cohort study included 1583 unique pa-
tients who underwent RET gene testing in one of three centers
covering all of Denmark between September 1994 and De-
cember 2014. At the end of the study period on January 1, 2015,
the population of Denmark was 5,659,715 (www.dst.dk).
RET testing was performed in 1056, 459, and 104 patients
at (i) the Center for Genomic Medicine, Copenhagen Uni-
versity Hospital, (ii) the Department of Molecular Medicine,
Aarhus University Hospital, and (iii) the Department of En-
docrinology and Medicine, Aalborg University Hospital, re-
spectively. If tested in more than one center, patients were
considered only once. One patient was tested in all three
centers, while 34 patients were tested in two centers. This
yielded a total of 1583 unique patients of which 164 were
positive and 1419 negative for a RET mutation (Fig. 1).
RET testing was performed on genomic DNA extracted
from whole blood in 1581 patients. One patient harbored the
p.C634Y + p.Y791F tandem germline mutation. The ARUP
database classifies the p.Y791F sequence change as uncertain
(www.arup.utah.edu/database/) (30). However, because re-
cent evidence has classified the sequence change as neutral,
the patient was counted as a p.C634Y mutation alone (31,32).
Two patients with MTC were tested using formalin-fixed
paraffin-embedded tissue. Both patients were deceased at the
time of testing. One was tested using normal tissue, and one
using submandibular tissue suspected of MTC metastasis.
The latter proved positive for the L790F mutation, but due to
suspicion of a somatic mutation in the local metastasis, the
patient was excluded from our RET germline mutation cohort
(Fig. 1). The patient has been described elsewhere (33).
A MEN2 family was defined by (i) clinical workup in one
of the four MEN2 management centers in Denmark, (ii) a
unique mutation, or (iii) a molecular proven de novo mutation
(both parents of the index case tested mutation negative).
Indications for testing included MTC, PHEO, HPTH, HD,
and relatives at risk of MEN2, among others.
Methods
To assess criterion (i), data were provided by collaborators
from the four MEN2 management centers. For criteria (ii)
and (iii), data were provided by the three RET testing centers.
Sequence changes were defined as mutations if classified as
pathogenic in the continually updated ARUP database on
July 1, 2016 (30).
RET testing centers
Center for Genomic Medicine, Copenhagen University
Hospital. From September 1994 to December 1995, Sanger
sequencing of RET exons 10 and 11 was performed. Since
January 1996, June 1997, February 2000, and September
2007, analysis was expanded to exons 16, 13 + 14, 15, and
8 + 9, respectively. Since October 2014, next-generation se-
quencing (NGS) of all RET exons has been performed. Pre-
dictive testing of relatives at risk of MEN2 was performed in
the relevant exon only.
Polymerase chain reaction (PCR) was performed using the
primers described in Table 1. Sanger sequencing was carried
out in both directions using an ABI377 DNA sequencer as
previously described (33,34) or an ABI3730 genetic ana-
lyzer, and the sequences were analyzed manually or by the
use of SeqScape (Applied Biosystems).
NGS was carried out using biotinylated oligos (Roche
NimbleGen) designed to capture all exons from the NM_
020975 transcripts. Library construction was carried out
using 500 ng of genomic DNA. The DNA was fragmented
into an average size of 200 bp using a Covaris S2 AFA
ultrasonicator, and adaptors from Illumina or Roche Nim-
bleGen were ligated to the fragments. Illumina adaptors
included in the TruSeq DNA LT Sample Preparation Kit
were attached using an SPRI-works System I for the Illu-
mina Genome Analyzer (Beckman Coulter). Adaptor se-
quences provided by Roche NimbleGen (SeqCap Adaptor
Kit A/B) were ligated using the KAPA HTP Library Pre-
paration Kit Illumina on a Sciclone G3 NGS Workstation
(PerkinElmer). Sequence capture was performed using a
double capture protocol (Roche NimbleGen), where 6–12
FIG. 1. Flow chart showing patients and families tested
for REarranged during Transfection (RET) mutations in
Denmark 1994–2014. The Center for Genomic Medicine,
Department of Molecular Medicine, and Department of
Endocrinology and Medicine are part of Copenhagen Uni-
versity Hospital, Aarhus University Hospital, and Aalborg
University Hospital, respectively.
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samples are multiplexed prior to hybridization. Finally,
2 · 76 bp paired-end sequencing was performed on the Il-
lumina MiSeq platform to an average depth of at least
100 · .
Department of Molecular Medicine, Aarhus University
Hospital. From October 1995 to January 1996, Sanger se-
quencing of exons 10 and 11 was performed. Since February
1996, October 1996, December 1998, September 2004, and
September 2007, testing was expanded to exons 16, 13 + 14,
8 + 9, and 15, respectively. Until 2000, only the cysteine
domains were tested. As testing has improved, some old
blood samples initially negative of RET mutations were re-
tested. Predictive testing of relatives at risk of MEN2 was
performed in the relevant exon only.
PCR was carried out using genomic DNA extracted from
EDTA-stabilized blood. The primers are shown in Table 1. Se-
quencing was carried out in both directions on an ABI3130XL or
ABI350XL Genetic Analyzer, and sequences were analyzed
using Gensearch software (Phenosystems).
Department of Endocrinology and Medicine, Aalborg Uni-
versity Hospital. From November 1996 to July 2002,
primer-specific PCR amplification to detect the p.C611Y
mutation was performed. The method has been described in
detail previously (35).
Approvals
The investigation was approved by the Danish Health
Authority (3-3013-395/2) and the Danish Data Protection
Agency (13/19275).
Results
RET testing of 1583 patients detected 14 different germline
mutations in 163 patients from 36 apparently unrelated
families. Twelve families were defined by either a unique or
de novo mutation, while the remaining were defined by
clinical workup (Table 2). Of the 36 families, 30 (83%) had
MEN2A and six (17%) had MEN2B.
Accounting for 36% of all families, RET germline muta-
tions of codon 611 were the most frequent. Subsequently,
mutations of codons 634 (17%), 918 (14%), 618 (11%), 620
(8%), 631 (3%), 790 (3%), 804 (3%), 852 (3%), and 883 (3%)
followed (Table 3). No mutations of codons 292, 515, 533,
609, 630, 666, 750, 768, 891, 904, or 912 were identified.
Among the 13 families with codon 611 mutations, 12 had
the p.C611Y mutation, while one had the p.C611W mutation.
Table 1. Primers and Polymerase Chain Reaction Conditions for Amplification
of RET Exons from the Two Major RET Testing Centers in Denmark
RET center Exon Primer sequences
Center for Genomic Medicine, Copenhagen
University Hospital
8 5¢-CTG TCT TTG CTG CCC TGG GTC TGT CAC-3¢
5¢-CGT TTC CAC CGG TGC CAT-3¢
9 5¢-GCT GGC AAG GCT CTG TAT ATG GT-3¢
5¢-GGA GGC TCA GCT TGA TGC ATA GAA C-3¢
10 5¢-TCA GAA AGG CAC TGT GAC CAA GC-3¢
5¢-TCC TGG GTG GAG TAA CAG AGG C-3¢
11 5¢-GAG CAT ACG CAG CCT GTA CCC AG-3¢
5¢-GAA ATG GGG GCA GAA CAC A-3¢
13 5¢-CAG GAA CAT AAT GCC ACA TAC AC-3¢
5¢-CCG TGG ACT CAG CTA GAC ACA-3¢
14 5¢-GCT CCT GGA AGA CCC AAG-3¢
5¢-TGG TGG AGT CAG GGT GTG ACA-3¢
15 5¢-CAG GTC TCA CCA GGC CGC TAC-3¢
5¢-AAG GGC CTC GGG TCA GTA TGC T-3¢
16 5¢-CTG TGC CCA GGA GTG TCT ACA GC-3¢
5¢-CCA GCC ATT TGC CTC ACG AAC ACA T-3¢
Department of Molecular Medicine,
Aarhus University Hospital
8 5¢-CCT TGG GCT CCA TCC GT-3¢
5¢-CCC CAG GAC CCC GTT T-3¢
9 5¢-TAT GGT GTT TCC CTA CTC A-3¢
5¢-CAG GTT TCC CCT ACT ATC-3¢
10 5¢-GCG CCC CAG GAG GCT GAG TG-3¢
5¢-TGC TGT TGA GAC CTC TGT GG-3¢
11 5¢-CTC GAT GGG GTG TTC TCA GG-3¢
5¢-GGA GGG CAG GGG ATC TTC-3¢
13 5¢-GCA GGC CTC TCT GTC TGA ACT T-3¢
5¢-GGA GAA CAG GGC TGT ATG GA-3¢
14 5¢-TCC TGG AAG ACC CAA GCT GC-3¢
5¢-CAT GGT GGG CTA GAG TGT GG-3¢
15 5¢-CCC CCG GCC CAG GTC TCA C-3¢
5¢-GCT CCA CTA ATC TTC GGT ATC TTT-3¢
16 5¢-TCT CCT TTA CCC CTC CTT CC-3¢
5¢-CCT GGC CAA GCT GCA CAG AC-3¢
RET, REarranged during Transfection.
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The distribution of RET germline mutations reported in
European and non-European studies is shown in Tables 3 and 4.
Discussion
In this nationwide study of 1583 patients who were RET
tested from 1994 to 2014, 14 different RET germline muta-
tions were identified in 163 patients from 36 apparently un-
related MEN2 families. Mutations of codon 611 were the
most prevalent (36%), followed by mutations of codon 634
(17%).
Limitations
To estimate the true number of RET mutations in a country,
the entire population needs to be tested. However, this would
result in both immense socioeconomic and ethical chal-
lenges. For the best possible estimate under the given cir-
cumstances, this study included all RET tested patients in
Denmark since testing became available and for more than
two decades onwards.
To capture yet unrecognized MEN2 patients, the Danish
MEN taskforce has recommended routine RET screening in
all patients with MTC, PHEO, C-cell or parathyroid hyper-
plasia, familial/recurrent HPTH, and HPTH <40–50 years of
age (36,37). Unfortunately, the completeness of RET screen-
ing in these patient groups is unknown and will require further
studies. In most other studies, only patients with MTC, clin-
ically diagnosed MEN2, or relatives at risk of MEN2 were
submitted to mutational analysis of RET (7–29,38,39).
To establish a nationwide RET positive MEN2 cohort, data
were collected in collaboration with the RET testing and
MEN2 management centers in Denmark. This might cause
Table 2. Families with Detected RET Germline Mutationsa in Denmark from 1994 to 2014
According to Family Number, Exon, Nucleotide and Sequence Change,
RET Status in Tested Cases, and Reference of Earlier Report
Family no. Exon Nucleotide change Sequence change RET+b/RET– Ref.
1c 10 c.1833C>G p.C611W 6/11
2 10 c.1832G>A p.C611Y 2/0 (43)
3 10 c.1832G>A p.C611Y 1/0
4 10 c.1832G>A p.C611Y 8/3
5 10 c.1832G>A p.C611Y 15/13
6 10 c.1832G>A p.C611Y 2/0 (34)
7 10 c.1832G>A p.C611Y 9/7 (34)
8 10 c.1832G>A p.C611Y 2/6
9 10 c.1832G>A p.C611Y 26/27
10 10 c.1832G>A p.C611Y 30/30 (44)
11 10 c.1832G>A p.C611Y 1/3
12 10 c.1832G>A p.C611Y 5/18 (45)
13 10 c.1832G>A p.C611Y 7/8
14 10 c.1853G>T p.C618F 1/1
15 10 c.1853G>T p.C618F 2/1 (34)
16 10 c.1853G>A p.C618Y 5/9
17 10 c.1853G>A p.C618Y 3/3 (34)
18 10 c.1858T>C p.C620R 6/5
19 10 c.1858T>C p.C620R 3/3 (34)
20d 10 c.1858T>C p.C620R 1/3 (34)
21c 11 c.1891G>T p.D631Y 1/0
22 11 c.1900T>C p.C634R 1/1
23 11 c.1900T>C p.C634R 1/2 (34)
24 11 c.1900T>C p.C634R 3/11 (44)
25 11 c.1900T>C p.C634R 1/5 (34)
26c,e 11 c.1901G>A p.C634Y 2/0
27c,e 11 + 13 c.1901G>A+c.2372A>T p.C634Y+Y791F 1/2
28c 13 c.2370G>T p.L790F 5/2
29c 14 c.2410G>A p.V804M 2/1
30c 14 c.2556C>G p.I852M 3/4
31c,d 15 c.2647_2648GC>TT p.A883F 1/3 (46)
32d 16 c.2753T>C p.M918T 1/4 (47)
33d 16 c.2753T>C p.M918T 1/3
34 16 c.2753T>C p.M918T 1/2
35d 16 c.2753T>C p.M918T 3/2 (48)
36 16 c.2753T>C p.M918T 1/1
Total 36 163/194
aSequence changes classified as pathogenic in the ARUP database July 1, 2016 (30).
bRET+ includes index cases.
cFamilies with unique mutations in Denmark.
dFamilies in which both parents of the index case were tested mutation negative.
eFamilies immigrated to Denmark. Family 26 and family 27 originate from Greece and Latvia, respectively.
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issues of inter-variability in regards to methods and inter-
pretation of results. However, methods and temporal ex-
pansion of RET testing were roughly similar in the two major
RET testing centers, accounting for 94.7% (1499 patients) of
the cohort. The remaining 84 patients were tested solely at the
Aalborg University Hospital and thus only for the p.C611Y
mutation. Of those, 26 were p.C611Y positive, and 45 were
related to a p.C611Y patient. This leaves only 13 patients
(0.7% of the total cohort) in which a RET mutation different
from the p.C611Y might have been missed.
To estimate the true number of unrelated MEN2 families,
a haplotype or genealogy study would be ideal. However,
24/36 apparently unrelated MEN2 families were defined by
thorough clinical work-up. As in other studies, this workup is
based on the index patient’s recollection and knowledge of
the familial history. Thus, possible relations between families
carrying similar mutations might have been missed and may
cause an overestimation of the number of families.
Codon 611 mutations
In the present study, mutations in codon 611 of exon 10 were
the most prevalent accounting for 36% of the 36 families. This
appears to be an unusually high prevalence. Numerous other
studies did not detect any mutations in codon 611, despite sys-
tematic testing of RET exon 10 (8–10,16–19,21–26,28,29,39).
Most of these are single-center studies, and there might be an
expectation of capturing more MEN2 patients in a nationwide
study such as the one presented here. However, this does not
seem to be the explanation. In fact, in three large European
predominantly multicenter series based on a total of 232, 191,
and 97 families, the prevalence of codon 611 mutations was only
0%, 3%, and 1%, respectively (Table 3) (6,7,12,13). The highest
prevalence rates reported have been from Portugal (40%), Saudi
Arabia (11%), and Iran (9%). However, these reports were based
on small mainly single-center studies with a total of 5, 11, and
9 families (20,27,38).
Mutations highly prevalent in other series
An unusually high prevalence of specific RET mutations has
also been described in other populations (6,7,26,28,29). In Cy-
prus, eight families were studied, and all carried the p.C618R
mutation (28). A Sardinian study of seven families found three
kindreds (43%) with the p.V804M mutation (29). In a large
Italian multicenter study, 22% and 10% of the families had
mutations in codons 804 and 891, respectively (Table 3) (7).
A large German study identified codon 790 mutations in 14%
of all included families, while a recent Greek study of 58
families found that 36% harbored the p.G533C mutation in
exon 8 (Table 3) (6,26).
Results from these studies indicate geographical differences
in the distribution of RET mutations. On the other hand, if
mutations in exon 8 are disregarded in the Greek study, the
distribution of mutations would be largely similar to that of
other sizeable series where exon 8 was not routinely tested
(7,12,13). Also, the high prevalence of codon 804 and 891
mutations in Italy may be caused by an earlier and more ex-
tensive testing of exons 14 and 15 compared to other series. A
similar explanation for the high prevalence of codon 611 mu-
tations in Denmark seems unlikely, since the traditional RET
panel included testing of exon 10 from the very beginning (40).
Table 4. Distribution of RET Germline Mutationsa Outside Europeb
Exon RET mutation
China China India Iran China Korea
S (17) S (18) S (19) M (20) (21) M (22)
n (%) n (%) n (%) n (%) n (%) n (%)
5 p.V292M 0 1 (9) 0 0 0 0
8 p.C515S 0 0 0 0 0 0
8 p.G533C 0 0 0 0 0 0
10 p.C609R/G/F/S/Y 0 0 2 (13) 0 0 0
10 p.C611R/G/F/S/W/Y 0 0 0 1 (9) 0 0
10 p.C618R/G/F/S/Y 2 (20) 1 (9) 1 (7) 1 (9) 0 3 (23)
10 p.C620R/G/F/S/W/Y 0 0 0 0 0 0
11 p.C630R/F/Y 0 0 0 1 (9) 0 0
11 p.D631Y 0 0 0 0 0 0
11 p.C634R/G/F/S/W/Y 6 (60) 8 (73) 9 (60) 6 (55) 15 (75) 10 (77)
11 p.K666E 0 0 0 0 0 0
12 p.A750P 0 0 0 0 0 0
13 p.E768D 0 0 0 0 0 0
13 p.L790F 1 (10) 1 (9) 0 0 0 0
14 p.V804L/M 0 0 1 (7) 1 (9) 0 0
14 p.I852M 0 0 0 0 0 0
15 p.A883F/T 0 0 0 0 0 0
15 p.S891A 0 0 0 0 0 0
15 p.S904F 0 0 0 0 0 0
16 p.R912P 0 0 0 0 0 0
16 p.M918T 1 (10) 0 2 (13) 1 (9) 5 (25) 0
Total 10 (100) 11 (100) 15 (100) 11 (100) 20 (100) 13 (100)
Due to rounding up, not all sums of the numbers fit.
aSequence changes classified as pathogenic in the ARUP database July 1, 2016 (30).
bIncluding series with a minimum of 10 European RET families ((25,38,39) excluded), a minimum of exons 10–11 and 13–16 tested
((23,24) excluded), and specifying familial prevalence.
S, single center; M, multicenter; n, number of families.
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Thus, there seems to be a genuine high prevalence of codon 611
mutations in Denmark. This is supported by the fact that 70%
(114/163) of the patients studied carry a codon 611 mutation.
Possible founder effect
Among the 13 apparently unrelated families with codon
611 mutations in the present study, 12 had the p.C611Y
mutation. This could indicate a possible founder effect for the
p.C611Y mutation. A similar effect has been indicated in
other studies (7,26–29,41,42).
In the Mediterranean islands of Cyprus and Sardinia, the
authors suggested that a founder effect for the p.C618R and
the p.V804M mutation could be explained by geographical
isolation (28,29). However, geographical isolation alone does
not seem to explain a possible founder effect in Denmark,
since its southern border connects the country to Germany
and the rest of Continental Europe.
In Greece, the p.G533C mutation was found especially in
the southern part of Central Greece and the southeast region
of the Peloponnese (26). In Italy, the p.S891A mutation was
mainly present in a well-defined northern area. The Italian
authors also found a high prevalence of codon 804 mutations,
but excluded a founder effect by single-nucleotide poly-
morphism analysis (7). Only few and very small studies have
proven a founder effect of RET mutations in mainland areas
by haplotype analysis (27,41,42). To elaborate on this ques-
tion in Denmark, further investigations are planned.
Prevalence of other mutations
Codon 634 mutations have been reported as the most
predominant in several European (Table 3) (6–14) and non-
European series (Table 4) (17–25). This might be explained
by earlier onset of disease and a presentation frequently in-
volving the full-blown MEN2 syndrome (MTC, PHEO, and
HPTH). Mutations of codon 634 were the second most fre-
quent alteration found in the present study, accounting for
17% (Table 3).
In the three largest studies to date, the prevalence of the
p.V804L/M mutations ranged from 10% to 22% (Table 3)
(6,7,12,13). In the present cohort, only one family (3%) was
identified with this mutation. Despite testing for mutations in
exon 14 since 1996 and 1997 in the two major RET testing
centers, one center did not test the non-cysteine domains until
after 2000. Retesting of patients tested before 2000 was
performed but not systematically. Consequently, some pa-
tients tested for these mutations between 1996 and 2000
might have been missed, and this may result in a reduced
number of families with non-cysteine codon 804 mutations.
The distribution of the remaining mutations did not differ
largely from that found in the literature.
Conclusion
The distribution of RET mutations in Denmark appears to
differ from that of other populations. Mutations in codon 611
were by far the most prevalent alterations followed by more
frequently reported mutations. This might be due to a pos-
sible founder effect for the p.C611Y mutation. However,
further studies are needed to find possible explanations for the
skewed mutational spectrum in Denmark.
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